Regeneron Pharmaceuticals, Inc. (0R2M.L)
USD 732.14
(-1.06%)
USD 732.14
(-1.06%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.7 Billion USD | 0.06% |
| 2022 | 2.7 Billion USD | 0.06% |
| 2021 | 2.69 Billion USD | 0.15% |
| 2020 | 2.69 Billion USD | 277.6% |
| 2019 | 713.9 Million USD | 0.76% |
| 2018 | 708.5 Million USD | 0.72% |
| 2017 | 703.45 Million USD | 46.21% |
| 2016 | 481.12 Million USD | 28.13% |
| 2015 | 375.51 Million USD | -18.2% |
| 2014 | 459.06 Million USD | -9.19% |
| 2013 | 505.51 Million USD | 10.54% |
| 2012 | 457.32 Million USD | 5.0% |
| 2011 | 435.53 Million USD | 172.16% |
| 2010 | 160.03 Million USD | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 5.09 Million USD | -97.48% |
| 2007 | 202.29 Million USD | 1.15% |
| 2006 | 200 Million USD | 0.0% |
| 2005 | 200 Million USD | 0.0% |
| 2004 | 200 Million USD | -6.46% |
| 2003 | 213.81 Million USD | 6.83% |
| 2002 | 200.15 Million USD | -0.21% |
| 2001 | 200.57 Million USD | 7381.39% |
| 2000 | 2.68 Million USD | -34.61% |
| 1999 | 4.1 Million USD | -2.38% |
| 1998 | 4.2 Million USD | -25.0% |
| 1997 | 5.6 Million USD | -35.63% |
| 1996 | 8.7 Million USD | -8.42% |
| 1995 | 9.5 Million USD | -22.76% |
| 1994 | 12.3 Million USD | 64.0% |
| 1993 | 7.5 Million USD | 10.29% |
| 1992 | 6.8 Million USD | 142.86% |
| 1991 | 2.8 Million USD | 0.0% |
| 1990 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 2.7 Billion USD | 0.01% |
| 2024 Q3 | 2.7 Billion USD | 0.01% |
| 2024 Q2 | 2.7 Billion USD | 0.01% |
| 2023 Q1 | 2.7 Billion USD | 0.01% |
| 2023 Q2 | 2.7 Billion USD | 0.01% |
| 2023 FY | 2.7 Billion USD | 0.06% |
| 2023 Q3 | 2.7 Billion USD | 0.01% |
| 2023 Q4 | 2.7 Billion USD | 0.01% |
| 2022 Q2 | 2.7 Billion USD | 0.01% |
| 2022 Q4 | 2.7 Billion USD | 0.01% |
| 2022 FY | 2.7 Billion USD | 0.06% |
| 2022 Q1 | 2.7 Billion USD | 0.03% |
| 2022 Q3 | 2.7 Billion USD | 0.01% |
| 2021 Q3 | 2.69 Billion USD | 0.04% |
| 2021 Q4 | 2.69 Billion USD | 0.04% |
| 2021 Q1 | 2.69 Billion USD | 0.04% |
| 2021 FY | 2.69 Billion USD | 0.15% |
| 2021 Q2 | 2.69 Billion USD | 0.03% |
| 2020 FY | 2.69 Billion USD | 277.6% |
| 2020 Q4 | 2.69 Billion USD | 0.03% |
| 2020 Q1 | 715.2 Million USD | 0.18% |
| 2020 Q2 | 2.21 Billion USD | 209.83% |
| 2020 Q3 | 2.69 Billion USD | 21.61% |
| 2019 Q3 | 712.7 Million USD | 0.2% |
| 2019 Q4 | 713.9 Million USD | 0.17% |
| 2019 Q2 | 711.3 Million USD | 0.2% |
| 2019 Q1 | 709.9 Million USD | 0.2% |
| 2019 FY | 713.9 Million USD | 0.76% |
| 2018 Q3 | 707.2 Million USD | 0.18% |
| 2018 Q1 | 704.64 Million USD | 0.17% |
| 2018 FY | 708.5 Million USD | 0.72% |
| 2018 Q2 | 705.9 Million USD | 0.18% |
| 2018 Q4 | 708.5 Million USD | 0.18% |
| 2017 FY | 703.45 Million USD | 46.21% |
| 2017 Q3 | 702.31 Million USD | 0.16% |
| 2017 Q4 | 703.45 Million USD | 0.16% |
| 2017 Q1 | 707.6 Million USD | 47.07% |
| 2017 Q2 | 701.17 Million USD | -0.91% |
| 2016 Q4 | 481.12 Million USD | 25.87% |
| 2016 FY | 481.12 Million USD | 28.13% |
| 2016 Q2 | 361.52 Million USD | -0.2% |
| 2016 Q3 | 382.22 Million USD | 5.73% |
| 2016 Q1 | 362.23 Million USD | -3.54% |
| 2015 Q2 | 388.04 Million USD | -17.87% |
| 2015 Q1 | 472.47 Million USD | 2.92% |
| 2015 Q4 | 375.51 Million USD | -4.9% |
| 2015 Q3 | 394.86 Million USD | 1.76% |
| 2015 FY | 375.51 Million USD | -18.2% |
| 2014 Q4 | 459.06 Million USD | -18.79% |
| 2014 FY | 459.06 Million USD | -9.19% |
| 2014 Q1 | 531.11 Million USD | 5.06% |
| 2014 Q2 | 517.84 Million USD | -2.5% |
| 2014 Q3 | 565.31 Million USD | 9.17% |
| 2013 Q3 | 482.17 Million USD | 1.87% |
| 2013 Q2 | 473.3 Million USD | 2.28% |
| 2013 Q1 | 462.74 Million USD | 1.19% |
| 2013 FY | 505.51 Million USD | 10.54% |
| 2013 Q4 | 505.51 Million USD | 4.84% |
| 2012 Q4 | 457.32 Million USD | 1.24% |
| 2012 Q2 | 446.23 Million USD | 1.22% |
| 2012 Q1 | 440.83 Million USD | 1.22% |
| 2012 FY | 457.32 Million USD | 5.0% |
| 2012 Q3 | 451.73 Million USD | 1.23% |
| 2011 Q1 | 160.15 Million USD | 0.08% |
| 2011 Q4 | 435.53 Million USD | 171.53% |
| 2011 FY | 435.53 Million USD | 172.16% |
| 2011 Q2 | 160.33 Million USD | 0.11% |
| 2011 Q3 | 160.4 Million USD | 0.04% |
| 2010 Q1 | 156.89 Million USD | 0.0% |
| 2010 Q2 | 157.8 Million USD | 0.58% |
| 2010 Q3 | 159.01 Million USD | 0.77% |
| 2010 Q4 | 160.03 Million USD | 0.64% |
| 2010 FY | 160.03 Million USD | 0.0% |
| 2009 Q4 | - USD | -100.0% |
| 2009 Q1 | - USD | -100.0% |
| 2009 Q3 | 62.57 Million USD | -0.56% |
| 2009 FY | - USD | -100.0% |
| 2009 Q2 | 62.92 Million USD | 0.0% |
| 2008 FY | 5.09 Million USD | -97.48% |
| 2008 Q2 | 118.65 Million USD | -40.67% |
| 2008 Q3 | 117.5 Million USD | -0.97% |
| 2008 Q4 | 5.09 Million USD | -95.67% |
| 2008 Q1 | 200 Million USD | -1.13% |
| 2007 Q2 | 200 Million USD | 0.0% |
| 2007 Q3 | 200 Million USD | 0.0% |
| 2007 Q4 | 202.29 Million USD | 1.15% |
| 2007 FY | 202.29 Million USD | 1.15% |
| 2007 Q1 | 200 Million USD | 0.0% |
| 2006 Q3 | 200 Million USD | 0.0% |
| 2006 Q1 | 200 Million USD | 0.0% |
| 2006 FY | 200 Million USD | 0.0% |
| 2006 Q2 | 200 Million USD | 0.0% |
| 2006 Q4 | 200 Million USD | 0.0% |
| 2005 Q4 | 200 Million USD | 0.0% |
| 2005 Q3 | 200 Million USD | 0.0% |
| 2005 Q2 | 200 Million USD | 0.0% |
| 2005 Q1 | 200 Million USD | 0.0% |
| 2005 FY | 200 Million USD | 0.0% |
| 2004 Q3 | 200 Million USD | 0.0% |
| 2004 Q2 | 200 Million USD | 0.0% |
| 2004 FY | 200 Million USD | -6.46% |
| 2004 Q4 | 200 Million USD | 0.0% |
| 2004 Q1 | 200 Million USD | -6.46% |
| 2003 Q2 | 205.14 Million USD | 2.54% |
| 2003 FY | 213.81 Million USD | 6.83% |
| 2003 Q4 | 213.81 Million USD | 2.16% |
| 2003 Q3 | 209.29 Million USD | 2.02% |
| 2003 Q1 | 200.06 Million USD | -0.04% |
| 2002 Q3 | 200.23 Million USD | -0.04% |
| 2002 Q4 | 200.15 Million USD | -0.04% |
| 2002 Q1 | 200.46 Million USD | -0.06% |
| 2002 Q2 | 200.32 Million USD | -0.07% |
| 2002 FY | 200.15 Million USD | -0.21% |
| 2001 Q4 | 200.57 Million USD | 9147.4% |
| 2001 FY | 200.57 Million USD | 7381.39% |
| 2001 Q1 | 2.45 Million USD | -8.58% |
| 2001 Q2 | 2.31 Million USD | -5.47% |
| 2001 Q3 | 2.16 Million USD | -6.39% |
| 2000 FY | 2.68 Million USD | -34.61% |
| 2000 Q1 | 3.87 Million USD | -5.56% |
| 2000 Q3 | 3 Million USD | -12.75% |
| 2000 Q2 | 3.44 Million USD | -11.11% |
| 2000 Q4 | 2.68 Million USD | -10.72% |
| 1999 Q1 | 3.9 Million USD | -7.14% |
| 1999 FY | 4.1 Million USD | -2.38% |
| 1999 Q3 | 3.3 Million USD | -10.81% |
| 1999 Q2 | 3.7 Million USD | -5.13% |
| 1999 Q4 | 4.1 Million USD | 24.24% |
| 1998 Q1 | 4.8 Million USD | -14.29% |
| 1998 Q2 | 4.8 Million USD | 0.0% |
| 1998 Q3 | 4.5 Million USD | -6.25% |
| 1998 Q4 | 4.2 Million USD | -6.67% |
| 1998 FY | 4.2 Million USD | -25.0% |
| 1997 Q1 | 7.8 Million USD | -10.34% |
| 1997 FY | 5.6 Million USD | -35.63% |
| 1997 Q3 | 6.8 Million USD | -6.85% |
| 1997 Q4 | 5.6 Million USD | -17.65% |
| 1997 Q2 | 7.3 Million USD | -6.41% |
| 1996 Q1 | 8.7 Million USD | -8.42% |
| 1996 Q4 | 8.7 Million USD | -3.33% |
| 1996 Q3 | 9 Million USD | 4.65% |
| 1996 FY | 8.7 Million USD | -8.42% |
| 1996 Q2 | 8.6 Million USD | -1.15% |
| 1995 Q1 | 8.7 Million USD | -29.27% |
| 1995 Q3 | 10.3 Million USD | -6.36% |
| 1995 Q4 | 9.5 Million USD | -7.77% |
| 1995 Q2 | 11 Million USD | 26.44% |
| 1995 FY | 9.5 Million USD | -22.76% |
| 1994 Q2 | 9.4 Million USD | -21.01% |
| 1994 Q1 | 11.9 Million USD | 58.67% |
| 1994 FY | 12.3 Million USD | 64.0% |
| 1994 Q4 | 12.3 Million USD | 19.42% |
| 1994 Q3 | 10.3 Million USD | 9.57% |
| 1993 Q3 | 7.7 Million USD | -1.28% |
| 1993 FY | 7.5 Million USD | 10.29% |
| 1993 Q2 | 7.8 Million USD | 1.3% |
| 1993 Q1 | 7.7 Million USD | 13.24% |
| 1993 Q4 | 7.5 Million USD | -2.6% |
| 1992 Q4 | 6.8 Million USD | 9.68% |
| 1992 Q3 | 6.2 Million USD | 8.77% |
| 1992 Q2 | 5.7 Million USD | 18.75% |
| 1992 Q1 | 4.8 Million USD | 71.43% |
| 1992 FY | 6.8 Million USD | 142.86% |
| 1991 Q3 | 800 Thousand USD | 100.0% |
| 1991 FY | 2.8 Million USD | 0.0% |
| 1991 Q2 | 400 Thousand USD | 0.0% |
| 1991 Q4 | 2.8 Million USD | 250.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -7297.909% |
| Dynavax Technologies Corporation | 256.91 Million USD | -952.064% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -6408.777% |
| Perrigo Company plc | 4.07 Billion USD | 33.645% |
| Illumina, Inc. | 2.26 Billion USD | -19.492% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 92.259% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -270190.0% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 71.709% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 81.007% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -1455.599% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -9914.45% |
| Waters Corporation | 2.35 Billion USD | -14.748% |
| Biogen Inc. | 7.33 Billion USD | 63.167% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -6993.481% |
| Evolus, Inc. | 126.54 Million USD | -2035.903% |
| Adicet Bio, Inc. | 17.7 Million USD | -15168.034% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -6161.496% |
| bluebird bio, Inc. | 330.32 Million USD | -718.252% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -399.661% |
| FibroGen, Inc. | 170.45 Million USD | -1485.697% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 1.174% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -12842.3% |
| Homology Medicines, Inc. | 44.05 Million USD | -6035.425% |
| Geron Corporation | 85.89 Million USD | -3046.602% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | -12.714% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | -507.313% |
| Myriad Genetics, Inc. | 145 Million USD | -1764.069% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -214415.873% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -2243.298% |
| Zoetis Inc. | 6.8 Billion USD | 60.269% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -61301.636% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | -24.686% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | -138.377% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -234.352% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -7341.291% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | -85.953% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -4570.48% |
| Verastem, Inc. | 41.55 Million USD | -6404.079% |
| Nektar Therapeutics | 230.4 Million USD | -1073.129% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -1350.272% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -87827.781% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | -93.505% |
| OPKO Health, Inc. | 326.56 Million USD | -727.678% |
| Exelixis, Inc. | 189.94 Million USD | -1322.998% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -530.929% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -1789900.0% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | -1852.835% |
| Imunon, Inc. | 1.13 Million USD | -237143.624% |
| Blueprint Medicines Corporation | 774.12 Million USD | -249.157% |
| Insmed Incorporated | 1.2 Billion USD | -124.494% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | -80.284% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -4642.928% |
| TG Therapeutics, Inc. | 110.79 Million USD | -2339.551% |
| Incyte Corporation | 38.28 Million USD | -6959.576% |
| Emergent BioSolutions Inc. | 877.5 Million USD | -208.023% |